Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer.
about
CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest.Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 DiabetesLow-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityProtocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyBeyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 TherapyTCR signaling fuels T(reg) cell suppressor function.Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2.Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice.Tuning IL-2 signaling by ADP-ribosylation of CD25.Tfr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells.Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
P2860
Q24306296-E2BE68F4-A472-4EE9-92CA-FFB22E2E96C2Q26770386-58D12F07-5764-41F2-9BAD-25B79385610BQ27008200-089FC8CE-DDE9-4F36-A818-825D21E9D9F1Q28604189-CCD351E8-F0B3-4C2A-A1C8-868F324A2E44Q34901832-92ECB943-5AEB-4C0A-9F64-41312F781B74Q35426986-B35F4255-07A7-4EA4-BC9A-049228DEEFD8Q36041794-F6A17BE6-A869-47FD-B1B6-E93FF6EBA2FEQ38262670-848E63D1-4BBD-4F26-9139-AD518424E6F3Q38424758-F2E7D47A-008D-4388-98E1-24C95FD57569Q38616032-27DDBD31-AD9C-4E21-B09E-729B5D1C5FCFQ38792909-3CCD9555-15D7-4E51-AFE4-41719F1F26C3Q38807853-91960B09-BA6E-4440-9EEF-D64437B85447Q39076924-1700EA65-4329-4B49-BAF2-0B27BFDE39EFQ41892598-DC105B0F-8766-462A-8582-8DC68A75EC02Q47831497-542EECE5-2A79-466E-B6DA-1CB9F51C994BQ49048342-203001A0-AC0F-43A9-8F7E-F7A613D76CBDQ55096330-F015A6C7-9253-4D7C-9A63-AA37DAA1E189
P2860
Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Sustained stimulation and expa ...... ction, vaccination and cancer.
@en
Sustained stimulation and expa ...... ction, vaccination and cancer.
@nl
type
label
Sustained stimulation and expa ...... ction, vaccination and cancer.
@en
Sustained stimulation and expa ...... ction, vaccination and cancer.
@nl
prefLabel
Sustained stimulation and expa ...... ction, vaccination and cancer.
@en
Sustained stimulation and expa ...... ction, vaccination and cancer.
@nl
P2093
P50
P1433
P1476
Sustained stimulation and expa ...... ction, vaccination and cancer.
@en
P2093
Benedicte Lambrecht
Estefania Casana
Gaelle Gottrand
Guillaume Churlaud
Gwladys Fourcade
Jesus Ruberte
Martin Amadoudji Zin
P304
P356
10.1016/J.CLIM.2014.02.003
P577
2014-02-19T00:00:00Z